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Nucleated cells are highly sensitive to hypoxia, 
and even short periods of ischemia in multi-
cellular organisms can have dramatic eff  ects on 
cellular morphology, gene transcription, and 
enzymatic processes. Mitochondria, as the ma-
jor site of oxygen metabolism, are particularly 
sensitive to changes in oxygen tension and dur-
ing hypoxia release reactive oxygen species 
(ROS), which chemically modify intracellular 
constituents such as lipids and induce damage 
to DNA leading to cell injury and death (1, 
2–5). In addition to endogenous intracellular 
events, ischemic tissue triggers an acute infl  am-
matory response that enhances cell injury, re-
sulting in necrosis. One current view is that 
ROS-modifi  ed structures formed during isch-
emia stimulate infi  ltration of infl  ammatory cells 
that mediate an acute infl  ammatory response 
leading to additional cell injury and death (6). 
However, this mechanism alone does not com-
pletely explain the acute nature of reperfusion 
injury (RI), because injury occurs even when 
infl  ammatory cells are limited (7, 8). Accumu-
lating evidence supports a major role for the 
serum innate response, namely natural IgM and 
the complement system. Early observations that 
transient depletion of complement C3 reduced 
infl  ammation in a rat model of myocardial in-
farction suggested a role for innate immunity in 
RI (9). Subsequently, Weisman et al. demon-
strated that pretreatment of rats with a specifi  c 
soluble inhibitor of complement C3 (sCR1) 
dramatically reduced injury in a similar model 
of myocardial infarction and further established 
the importance of complement as a mediator of 
injury (10). Subsequent studies using the sCR1 
inhibitor in various animal models, including 
porcine (11, 12) and mouse (13), and in various 
tissues as diverse as the central nervous system, 
intestine, or skeletal muscle confi  rmed and gen-
eralized the concept that the complement sys-
tem was an important mediator of RI. Although 
the complete mechanism of injury is not clear, 
a role for the complement membrane attack 
complex (C5–C9) is supported by observations 
of deposition of complement C9 within reper-
fused heart tissues (14, 15), reduction in injury 
in mice defi  cient in C5 or treated with C5-
specifi  c antibody (16–19), and C6-  defi  cient rab-
bits (20, 21). Importantly, RI injury in the 
skeletal muscle model is not only complement 
dependent but requires intact mast cells, as mice 
defi  cient in mast cell protease 5, one of the 
chymotryptic proteases found in granules, are 
protected from full injury (22).
The fi  rst indication that natural antibody was 
involved in initiation of RI derived from studies 
in mouse models bearing complete defi  cien-
cies in innate immune proteins such as com-
plement components C3 and C4 and natural 
IgM. Results from these studies suggested that 
brief periods of ischemia led to an   alteration in 
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surface epitopes, and this change resulted in binding by natu-
ral IgM and activation of the complement system (23, 24). 
Further support that specifi  c natural IgM was involved fol-
lowed from two separate reports that mice defi  cient in com-
plement receptors CD21 and CD35 were protected in an 
intestinal model of RI despite a normal level of circulat-
ing IgM (25, 26). Reconstitution of the animals with pooled 
IgM (isolated from WT mice) or engraftment with WT peri-
toneal B-1 cells restored pathogenic IgM and RI. Notably, 
reconstitution of Cr2−/− mice with pooled murine IgG alone 
did not restore histological injury but enhanced neutrophil 
infi  ltration when combined with IgM (25). Most recently, 
identifi  cation of a single monoclonal IgM from a panel of B-1 
cell hybridomas, which alone could restore injury in both 
  intestine and hindlimb models of RI in antibody-defi  cient 
(RAG-1−/−) mice, provided further support for the hypo-
thesis that innate recognition of stress-induced self-antigens 
was involved in initiation of RI (27, 28).
In this paper, we identifi  ed a highly conserved region within 
nonmuscle myosin heavy chain (Hc) type II (NMHC-II) A 
and C as the target for natural IgM and initiation of injury in 
murine models of skeletal and intestinal RI. Five lines of evi-
dence are provided that support a role for NMHC-II as the 
critical self-ligand in RI: (a) protein sequence analysis of nat-
ural IgM-bound NMHC-II isolated from lysates of RI tissue; 
(b) binding of NMHC-II by pathogenic IgM (IgM CM-22) in 
an ELISA assay; (c) initiation of intestinal RI in RAG-1−/− 
mice with an anti–pan-myosin antibody; (d) sequence ho-
mology with a synthetic peptide isolated from phage display 
library that binds pathogenic IgM CM-22 and blocks intestinal 
RI in WT mice; and (e) a synthetic peptide representing a 
conserved region of NMHC-II binds IgM CM-22 in vitro and 
blocks RI in WT mice in two distinct tissues. Collectively, 
these results support the model that natural IgM recognition 
of NMHC-II expressed on the surface of ischemic tissue re-
sults in activation of the complement system and acute in-
fl  ammation. These fi  ndings suggest a general mechanism by 
which stress, such as hypoxia, leads to expression of a highly 
conserved self-antigen on the cell surface and recognition by 
the innate immune system resulting in acute infl  ammation. 
These observations represent a clear example of the novel con-
cept “innate autoimmunity” (29, 30).
RESULTS
Immune precipitation of self-antigens with natural IgM
The identifi  cation of a B-1 cell hybridoma clone (IgM CM-22) 
that binds ischemic tissue in the murine intestinal and skeletal 
muscle models of RI provided support for the hypothesis that 
Figure 1.  Immune precipitation of ischemia-specifi  c antigens. 
(A) Detection of a unique band (arrowhead) at  250 kD on SDS-PAGE 
(8%). Size markers are indicated on the left. Intestinal lysates were pre-
pared from RAG-1−/− mice reconstituted with IgM CM-22 and either sham 
control (no ischemia) or subjected to ischemia, followed by reperfusion 
for 0 or 15 min. (B) In vitro binding of IgM CM-22 to NMHC-II. ELISA plates 
were coated with rabbit IgG antibodies specifi  c for each of the three dif-
ferent isoforms of NMHC-II (top left, isoform A; top right, isoform B; bot-
tom left, isoform C; or bottom right, anti–pan-myosin antibody). Bound 
myosin HC from intestinal lysates was detected by IgM CM-22 or CM-31. Re-
sults represent means ± SEM of OD 405 nm units and are representative 
of triplicate samples. (C) Anti–pan-myosin antibody restores RI in ische-
mic RAG-1−/− mice. RAG-1−/− mice were injected i.v. with saline (top left) 
or 50 µg of rabbit IgG anti–pan-myosin (bottom left), followed by RI 
treatment. (right) Scatter plot of pathology scores in which each symbol 
represents a single animal. *, P < 0.05.JEM VOL. 203, January 23, 2006  143
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ischemic tissue was altered relative to normal tissue and that 
neoepitopes expressed or exposed during ischemia were tar-
gets for an innate response to self (27, 28). Moreover, the 
availability of a specifi  c IgM provided a means to identify the 
neoepitope. The rationale was that circulating IgM would 
bind self-antigens exposed during ischemia and that these 
complexes could be isolated and the antigens identifi  ed by 
proteomic techniques. RAG-1−/− mice were reconstituted 
with an optimal amount of IgM CM-22, treated for intestinal 
ischemia, and reperfused for 0 or 15 min before harvesting 
of tissues. Immune complexes of IgM antigen were isolated 
from lysates of jejuneum at the two time points and fraction-
ated by SDS-PAGE under reducing conditions. Analysis of 
the stained gels indicated common bands at varying molecu-
lar masses for all time points, including the sham control (Fig. 
1 A). However, at 15 min an apparent unique band at high 
molecular mass ( 250 kD) was identifi  ed (Fig. 1 A). Protein 
bands were excised from stained gels and enzymatically di-
gested, and peptides were analyzed by tandem mass spec-
trometry as described previously (31). Analysis of eluted 
peptides indicated that the common bands at  25, 50, and 75 
kD represented immunoglobulin light chain and IgG and 
IgM Hc, respectively. The IgG Hc band at 50 kD was identi-
fi  ed as goat and most likely represents Ig eluting from the 
beads, whereas the 75-kD band represents murine IgM Hc. 
Analysis of the high molecular mass band yielded peptide 
  sequences homologous to NMHC-II isoforms A and C 
(Table I). In similar experiments using lysates prepared from 
WT mice treated for 3 h in intestinal RI, a similar size band 
at 250 kD was also observed and sequence analysis identifi  ed 
NMHC-II A and C peptides (unpublished data).
Three forms (A, B, and C) of NMHC-II have been iden-
tifi  ed in the mouse and human genomes (32, 33). All eukary-
otic cells express NMHC-II, but the distribution of the three 
isoforms varies. NMHC-II A and B are  85% homologous, 
whereas NMHC-II C is  65% similar to A and B (32). The 
three isotypes are highly conserved among mice and humans. 
As a further test for binding of IgM CM-22 to NMHC-II, an 
ELISA approach was followed. Plates were coated with anti-
body specifi  c for each of the three forms of NMHC-II or 
with a pan-myosin antibody to capture the relevant antigen 
from lysates prepared from jejuneum of RAG-1−/− mice. 
Subsequently, IgM CM-22 (or IgM CM-31) was added and devel-
oped with a labeled anti–mouse IgM antibody. Above back-
ground binding of IgM CM-22 but not IgM CM-31 to all three 
of the isoforms of NMHC-II was observed (Fig. 1 B). The 
combined sequence analysis and ELISA results suggest that 
IgM  CM-22 recognizes a conserved region of the type II 
NMHC. As a further test of whether myosin is exposed to 
circulating antibody after ischemia, RAG-1−/− mice were 
reconstituted with a purifi  ed IgG fraction of rabbit anti–pan-
myosin Hc. No evidence of rabbit IgG deposition was ob-
served in tissues of reconstituted but sham-treated mice 
(unpublished data). In contrast, ischemic RAG-1−/− mice 
reconstituted with the myosin-specifi  c IgG before reperfu-
sion developed signifi  cant RI compared with saline controls 
(33 ± 11 vs. 11 ± 8; P < 0.05; Fig. 1 C). These results pro-
vide further support that myosin is exposed to antibody in 
circulation after ischemia. However, they did not identify 
the epitope within NMHC-II.
Identifi  cation of an IgM CM-22 ligand by phage display
As an alternative approach to identify the IgM CM-22 target 
self-antigen, an M13 phage display library of random 12-mer 
amino acid sequences was screened with the specifi  c IgM. 
After four rounds of positive selection with IgM CM-22 and 
two rounds with negative selection with a control IgM (clone 
CM-75), 10 phage clones were isolated and the nucleotide 
sequence of the relevant M13 gene was analyzed. Notably, 
all 10 clones bore a codon sequence rich in asparagine. Four 
best binders to IgM CM-22 were selected and one of these 
clones, P8 (which bound with the highest effi   ciency), was 
further characterized (Table II and Fig. 2 A). A 12–amino 
acid peptide (P8) was synthesized based on the phage se-
quence and assayed for inhibition of phage P8 binding to 
IgM CM-22 (Fig. 2 B). Titration of increasing amounts of P8 
peptide yielded 50% inhibition at an estimated concentration 
of 10–100 µM. This assay indicates a reasonable overall avid-
ity of binding based on multiple binding sites expressed on 
the phage surface. This result also suggests that IgM CM-22 
binding to phage P8 is specifi  c for the peptide region and 
that the synthetic peptide could be used as a mimetope for 
the actual antigen. To further characterize binding of P8 pep-
tide to IgM CM-22, ELISA plates were coated with the peptide 
and tested with varying concentrations of IgM CM-22 or con-
trol IgM CM-75 for binding (Fig. 2 C). At the lower concen-
tration of 1 µg/ml, neither IgM bound above background. 
However, at 10 µg/ml signifi  cantly more IgM CM-22 bound 
than IgM CM-75 (P < 0.05).
Table I.  Tandem mass spectrometry results of isolated 
ischemic antigen
Matched proteins
Mass spectrometry
(sequenced peptides)
Mouse NMHC-II A
 (NP  071855;
 total  score  =130,
 peptides  matched  = 6)
VVFQEFR
CNGVLEGIR
K  F  D  Q  L  L  A  E  E  K 
K  F  D  Q  L  L  A  E  E  K 
E  Q  A  D  F  A  I  E  A  L  A  K 
Q  L  L  Q  A  N  P  I  L  E  A  F  G  N  A  K 
Mouse NMHC-II C
 (AAQ24173;
 total  score  = 133,
 peptides  matched  = 7)
CNGVLEGIR
VKPLLQVTR
K  F  D  Q  L  L  A  E  E  K 
K  F  D  Q  L  L  A  E  E  K 
E  Q  A  D  F  A  L  E  A  L  A  K 
L  A  Q  A  E  E  Q  L  E  Q  E  S  R 
Q  L  L  Q  A  N  P  I  L  E  A  F  G  N  A  K 
Immunoprecipitations were performed as described in Materials and methods. 
Bands obtained from SDS-PAGE were digested and extracted for protein identifi  ca-
tion by tandem mass spectrometry. Peptides identifi  ed from the RI-specifi  c 250-kD 
band were matched to isoforms A and C from NMHC-II. The Mascot score is defi  ned 
as −10 × Log(P), where P is the probability that the observed match is a random 
event. Individual ion scores >53 indicate identity or extensive homology (P < 0.05).144  TARGET SELF-ANTIGENS IN REPERFUSION INJURY | Zhang et al.
To test whether synthetic peptide P8 blocked IgM CM-22 
in vivo, antibody-defi  cient (RAG-1−/−) mice were reconsti-
tuted with pathogenic IgM with or without the peptide. Pre-
vious studies had demonstrated that intestinal RI in RAG-1−/− 
mice was IgM-dependent and that IgM CM-22 alone was suffi   -
cient to restore injury (24, 27). As expected, reconstitution of 
RAG-1−/− mice with IgM CM-22 but not saline before reper-
fusion resulted in RI (Fig. 3, A [i] and B). In contrast, mixing 
of IgM CM-22 with P8 peptide before injection in ischemic 
mice signifi  cantly blocked apparent injury (mean pathology 
score = 6 ± 3 vs. 31 ± 13; P < 0.001; Fig. 3, A [ii] and B). 
Previous titration of peptide with IgM CM-22 suggested that an 
optimal concentration of  10 µM of peptide was suffi   cient 
to block 200 μg IgM CM-22 (0.1–0.2 µM; unpublished data). 
Immunohistological analyses of serial sections of reperfused 
intestinal tissue (jejuneum) after RI identifi  ed colocalization 
of IgM and complement C4 and C3 within the microvilli in 
RAG-1−/− mice reconstituted with IgM CM-22 but no depo-
sition in sections prepared from mice receiving P8 peptide 
(unpublished data). No binding of IgM or complement was 
observed in IgM CM-22–reconstituted sham controls, nor in 
RAG-1−/− mice reconstituted with control IgM CM-31 or 
RAG-1−/− mice reconstituted with saline only (unpublished 
data) (27). Thus, peptide P8 appears to block binding of 
IgM CM-22 and induction of injury in vivo.
To test whether peptide P8 represented a mimetope for a 
major self-antigen, WT mice were pretreated with peptide 
P8 (serum concentration of  10 µM) 5 min before reperfu-
sion in the intestinal model. Analysis of jejuneum tissues of 
mice treated with a similar concentration of control peptide 
or saline before reperfusion identifi  ed signifi  cant injury to the 
microvilli, as expected (P < 0.05; Fig. 3 A, iii). In contrast, 
pretreatment of WT mice with peptide P8 5 min before 
reperfusion blocked apparent injury relative to saline or con-
trol peptide (mean pathology score = 5 ± 3 vs. 24 ± 16 and 
23 ± 19, respectively; P < 0.005 and P < 0.027, respec-
tively; Fig. 3, A [iv] and B). As expected, IgM, C4, and C3 
colocalized within microvilli of RI-treated WT mice but not 
in mice administered P8 peptide (unpublished data). These 
results suggest that the number of key epitopes required to 
  initiate RI is limited as a single peptide blocks injury and de-
position of IgM and complement.
Figure 2.  Screening of M13 phage display library identifi  es 
IgM CM-22–specifi  c peptides. (A) ELISA comparison of four phage clones 
isolated from an enriched pool IgM CM-22–selected phage. Phage clone P8 
binds with the highest relative effi  ciency (△, P1 clone; ×, P5 clone; 
□, P7 clone; ○, P8 clone; and ◇, control M13). Plate was coated with a 
  solution of IgM CM-22 before addition of varying concentrations of phage 
clones. (B) Synthetic peptide P8 inhibits IgM CM-22 binding of phage clone 
P8. ELISA was performed with varying concentrations of synthetic P8 
peptide added to an IgM CM-22–coated plate before the addition of 5 × 1011 
PFU phage. (C) ELISA assay for specifi  c binding of P8 peptide to IgM CM-22. 
Synthetic P8 peptide was coated on an ELISA plate followed by addition 
of saline, IgM CM-75, or IgM CM-22 at 1 (closed bar) or 10 (shaded bar) μg/ml. 
The bound IgM was detected by anti–mouse IgM-AP as described in Ma-
terials and methods. Results in A–C are representative of at least three 
independent experiments.
Table II.  Phage-displayed peptides bind to CM22 IgM and 
share conserved homology with NMHC-II
Peptides Sequences
Phage clone
 P8 N  G  N  N  V  N  G  N  R  N  N  N 
 Consensus XNNNxNNxNNNN
NMHC-II
  Mouse-II A (542–556) L  M  K  N  M  D  P  L  N  D  N  I 
  human-II A (585–596) L  M  K  N  M  D  P  L  N  D  N  I 
  Mouse-II B (592–603) L  M  K  N  M  D  P  L  N  D  N  V 
  human-II B (592–603) L  M  K  N  M  D  P  L  N  D  N  V 
  Mouse-II C (607–619) L  M  K  N  M  D  P  L  N  D  N  V 
  human-II C (701–802) L  M  K  N  M  D  P  L  N  D  N  V 
Control AGC MPY VRI PTA
Peptides identifi  ed by screening phage display library with IgM CM-22. Sequence of 
peptide region of phage clone P8 and consensus sequence based on 10 phage 
clones isolated from an IgM CM-22–selected pool of M13 phage display library. 
  Alignment of conserved regions of three isoforms of mouse and human NMHC-II 
is also provided. The corresponding amino acid positions in each isoform are listed 
in the parentheses. N2 peptide corresponds to the mouse and human NMHC-II 
C sequence.JEM VOL. 203, January 23, 2006  145
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Identifi  cation of self-peptide that binds IgM CM-22
Comparison of the sequences of the three NMHC-II iso-
forms with the P8 peptide sequence identifi  ed one region of 
apparent homology (Table II). All three isoforms include a 
motif of NxxxxNxNx that suggested similarity with the P8 
sequence. A 12–amino acid synthetic peptide (referred to as 
N2) sequence (represents the NMHC-II C isoform) was pre-
pared for further study. To test whether this region bound 
to IgM CM-22, surface plasmon resonance (SPR) analysis was 
used (Fig. 4). N2 peptide was injected over a surface coupled 
with IgM CM-22 (Fig. 4 A) and generated a robust response, 
which corresponded to a KD of 123 ± 61 μM (mean ± SD; 
n = 2) as calculated from the steady-state response levels (Fig. 
4 C). In contrast, no binding was observed when a control 
peptide was injected over the specifi  c IgM-coupled surface 
(Fig. 4 B) or when the N2 peptide was injected over a surface 
coupled with the IgM CM-31 control IgM (Fig. 4 D).
Self-peptide blocks intestinal RI injury
To test whether NMHC N2 peptide represents the major 
self-epitope in intestinal RI, WT mice were treated with sa-
line or increasing concentrations of the synthetic peptide 
  (fi  nal serum concentrations = 8, 16, 32, or 40 µM, respec-
tively) 5 min before reperfusion in the intestinal model. His-
tological analysis of tissue sections of saline-treated WT mice 
identifi  ed injury that correlated with deposition of IgM and 
complement as expected (Fig. 5, A [i], B, and D [i–iv]). In 
contrast, treatment of WT mice with an increasing concen-
tration of N2 peptide demonstrated a dose-dependent re-
duction in injury (mean pathology scores: saline, 22 ± 
17% [n = 9]; 8 µM, 21 ± 7% [n = 3; P < 0.40]; 16 µM, 
17 ± 5% [n = 3; P < 0.20]; 32 µM, 8 ± 6% [n = 3; P < 
0.03]; and 40 µM, 7 ± 4% [n = 7; P < 0.01]) (Fig. 5, A [ii] 
and B). Thus, signifi  cant protection from injury was achieved 
with 32- and 40-μM concentrations of N2 peptide. Interest-
ingly, P8 peptide was protective at a lower concentration 
(10 µM), correlating with its higher CM-22 binding affi   nity 
relative to N2.
To further evaluate the protection by N2 peptide, mice 
were characterized for intestinal permeability. In this assay 
mice are administered horseradish peroxidase (HRP) enter-
ally 10 min before ischemia, and uptake into circulation is 
Figure 3.  P8 peptide blocks RI in RAG-1−/− mice and WT animals. 
(A, i and ii) Representative sections (stained with hematoxylin and eosin) 
prepared after RI treatment in RAG-1−/− mice with IgM CM-22 alone or 
mixed with P8 peptide, respectively. (iii and iv) Representative sections 
prepared from WT mice and treated for intestinal RI that received either 
saline or P8 peptide 5 min before reperfusion. Arrowheads indicate 
Figure 4.  SPR. (A) Binding isotherms for samples of the N2 peptide 
with concentrations from 10.5 to 120 μM injected over the IgM CM-22–
coupled surface. (B) Binding isotherm for a same-length random se-
quence  control  peptide  (A G C M P Y V R I P T A )  injected  at  a  concentration  of 
117 μM over the IgM CM-22–coupled surfaces. (C) Nonlinear curve fi  tting 
with a 1:1 Langmuir binding isotherm to the steady-state response levels 
for the injection showed in A (χ2 = 10). (D) The binding isotherm for the 
injection of the N2 peptide at 120 μM over a surface coupled with con-
trol IgM CM-31. In A, B, and D, the injection phases had a duration of 240 s 
each, with the ends of the injection marked by arrows.
pathologic features of injury. Magnifi  cation, 200. (B) Scatter plot 
  indicates mean pathology score of each group of treated animals. Each 
symbol represents one animal. Control group is WT mice pretreated with 
a  control  peptide  (A G C M P Y V R I P T A )  at  a  similar  dose  of  P8  peptide. 
*, P < 0.05 as determined by Student’s t test of the P8 treated versus 
 untreated  groups.146  TARGET SELF-ANTIGENS IN REPERFUSION INJURY | Zhang et al.
measured after RI treatment. Hart et al. recently reported us-
ing a similar assay to measure intestinal permeability in RI-
treated mice but administered FITC–dextran (34). Our results 
indicate signifi  cant uptake of HRP into circulation in WT 
mice treated with saline versus sham controls (195.4 ± 51.7 
vs. 31 ± 17.3 [n = 8 and 5, respectively]; P < 0.05; Fig. 5 C). 
In contrast, mice pretreated with an optimal amount of N2 
peptide before reperfusion develop signifi  cantly less perme-
ability than saline-treated mice (79.8 ± 30 vs. 195.4 ± 51.7 
[n = 10 and 8, respectively]; P < 0.05; Fig. 5 C). Thus, pre-
treatment of mice with N2 peptide protects from both histo-
logical injury and intestinal permeability.
Protection from injury correlated with a reduction in de-
position of IgM and complement in mice treated with 40 µM 
N2 peptide (Fig. 5 D, v–viii). Notably, among the control 
mice not all animals developed full injury even though treat-
ment with N2 (or P8) peptide gave substantial protection. 
We speculate that the range in injury observed among WT 
Figure 5.  Treatment of mice with NMHC-II N2 peptide blocks 
  intestinal RI. (A) Representative sections prepared from WT mice treated 
for intestinal RI and injected i.v. with either saline (i) or 40 µM N2 peptide 
(ii) 5 min before reperfusion. (B) Scatter plot indicates mean pathology 
score of each group of treated animals. WT mice were injected with saline 
or varying concentrations (fi  nal serum concentrations of N2 are indi-
cated) of N2 peptide 5 min before reperfusion. Each symbol represents a 
single mouse. *, P < 0.05 as determined by Student’s t test. (C) Scatter 
plot indicates mean plasma levels of 40-kD HRP of each group of treated 
animals 3 h after reperfusion. WT mice were administered HRP by gavage 
10 min before the induction of intestinal RI and further treated with con-
trol, saline, or 40 µM N2 peptide 5 min before reperfusion. Each symbol 
represents a single mouse. *, P < 0.05, based on Student’s t test. (D) 32 
and 40 µM N2 peptide blocks IgM binding and activation of complement 
in intestinal RI. Representative cryosections of intestinal tissues were 
harvested after intestinal RI and treated with antibodies specifi  c for 
mouse IgM, C4, or C3. Magnifi  cation, 400. Results are representative of at 
least fi  ve experiments. Immunohistology was not performed on tissues 
harvested from mice treated with the lower doses of peptide. WT mice 
were without N2 (i–iv) or pretreated with N2 (v–viii). (i, iii, v, and vii) Sec-
tions were stained with anti-IgM–biotin, followed by streptavidin–Alexa 
568 (red), and counterstained with DAPI (violet). Sections in panels ii and 
vi were stained with anti-C4–FITC (green), and the sections in panels iv 
and viii were stained with anti-C3–FITC (green).JEM VOL. 203, January 23, 2006  147
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mice is caused by a variation in serum levels of specifi  c natu-
ral IgM because this pattern is not observed in RAG- 1−/− 
mice treated with IgM CM-22 (Fig. 3). Moreover, IgM and 
complement deposition correlate with the level of injury; 
i.e., WT mice with a low injury score have low level of IgM 
(unpublished data).
Previous reports identifi  ed vascular permeability of la-
beled albumin as a measure of severity of intestinal RI (23, 
26, 27). To evaluate further the eff  ects of treatment with N2 
peptide in the intestinal RI model, we used an intravital ap-
proach combined with a novel miniaturized laser scanning 
confocal microscope to image leakage of microvessels within 
the villi of the jejunum. In this approach anesthetized mice 
are administered a fl  uorescent-labeled vascular probe (Angio-
Sense 680) that circulates within normal blood vessels for up 
to 2 h. Besides its stability in circulation, an advantage of this 
novel probe is that it emits in the near infrared and, thus, im-
aging is in the low energy range. To image circulation within 
the microvilli, a scanning confocal stick lens (approximately 
the diameter of a biopsy needle) is inserted within a small in-
cision in the wall of the jejuneum and placed in direct contact 
with the mucosal surface. Contrast is provided by pretreat-
ment of mice i.v. with Rhodamine 6G, which is taken up by 
cells, especially the enterocytes lining the microvilli. Mice are 
injected with the vascular probe 5 min before reperfusion, 
and imaging is initiated 15 min after reperfusion. For exam-
ple, among the sham controls, the blood vessels within the 
lamina propria of microvilli are identifi  ed by the circulating 
vascular probe (red), which is contrasted by the green stain of 
the enterocytes (Rhodamine 6G; Fig. 6 A, i). In experimen-
tal mice, signifi  cant leakage of the vascular probe is observed 
as early as 20 min after reperfusion, as indicated by the pres-
ence of red dye within the lamina propria and surrounding 
target tissues. The mean ratio of vessel (V) to background (B) 
is 149 ± 14 versus 16 ± 4 in arbitrary units for sham controls 
and saline-treated mice, respectively (P < 0.001; Fig. 6, A [ii] 
and B). In contrast, limited leakage of the vascular probe was 
observed in experimental mice pretreated with N2 peptide 
(153 ± 4 vs. 149 ± 14 units for N2- and saline-treated mice, 
respectively; P < 0.001; Fig. 6, A [iii] and B). Thus, admin-
istration of an optimal amount of N2 peptide 5 min before 
reperfusion eff  ectively limited leakage of the vascular probe.
Self-peptide blocks RI injury in skeletal muscle
The identifi  cation of a single self-peptide that blocks intesti-
nal RI in WT mice led to the general question of whether 
the N2 region of NMHC-II was also the target for patho-
genic IgM among other ischemic tissues. It might be pre-
dicted that the number of antibodies specifi  c for ischemic 
tissue is limited based on the current understanding that the 
repertoire of natural IgM is relatively small (35–37) and pu-
tatively selected through evolution (38, 39). Moreover, li-
gands of natural IgM are considered highly conserved structures 
and are probably limited in number.
To test whether NMHC-II represents the self-ligand tar-
get in the murine hindlimb model, mice were treated for 2 h 
of ischemia followed by 3 h of reperfusion as described pre-
viously (28). As expected, WT mice administered saline or 
40-μM control peptide (Table II) developed considerable in-
jury. In contrast, injury was signifi  cantly reduced in mice ad-
ministered 40 μM (fi  nal serum concentration) of N2 peptide 
before reperfusion (mean number of injured muscle fi  bers 
per 50 counted = 25 ± 4 and 22 ± 3 for saline and control 
peptide, respectively, vs. 12 ± 1 for N2 treated; P < 0.01 and 
P < 0.05, as determined by Student’s t test between saline 
and control peptide and N2 and control peptide, respec-
tively; P < 0.05 for all groups, as determined by analysis of 
variance [ANOVA]) (Fig. 7, A and B). Thus, these results 
suggest that, as in the intestinal model, NMHC-II is the ma-
jor self-ligand in ischemic skeletal muscle.
Figure 6.  N2 peptide blocks vascular leak in intestinal RI. 
(A, i–iii) Representative images of microvilli within the jejuneum of sham, 
saline, or N2 administered mice, respectively. Mice were treated for RI as 
  described in Fig. 5, except that 5 min before reperfusion the later two 
groups were injected i.v. with a mixture of vascular probe (AngioSense 
680, red) and Rhodamine 6G (green) in saline or N2 peptide (40 μM fi  nal 
concentration). (i) Results of the sham group identify microvasculature of 
individual microvilli in which red indicates blood vessels and green out-
lines enterocytes and lamina propria. (ii) Saline group images indicate 
extensive leakage of the vascular probe into lamina propria and surround-
ing tissues. (iii) N2 peptide group results indicate relatively normal vascu-
lature within microvilli and limited leakage of vascular probe. (B) Scatter 
plot of ratio of intensity of signal of vessels (V) versus background (B). 
The horizontal lines indicate the mean of samples analyzed. Each symbol 
indicates a representative measurement from representative images 
of at least three mice per group, and means ± SD were calculated. 
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DISCUSSION
The recent identifi  cation of a natural antibody (IgM CM-22) 
that initiates intestinal and skeletal muscle RI in antibody-
defi  cient mice has provided an important reagent to isolate 
and characterize the self-antigen involved in initiation of 
acute infl  ammation (27, 28). In this paper, we provide fi  ve 
lines of evidence that support the identifi  cation of the self-
antigen as a highly conserved region (represented by N2 pep-
tide) within NMHC-II. Notably, pretreatment of WT mice 
with N2 peptide (or the mimetope P8) after ischemia but be-
fore reperfusion dramatically reduced RI within both intesti-
nal and skeletal muscle models.
15 types of myosin Hc have been identifi  ed to date. Like 
other myosins, the NMHC-II form hexamers of two Hc 
( 250 kD each) and two pair of regulatory light chains (20 
and 17 kD each). Functionally, they all bear ATPase activity, 
form molecular motors within the cell, and are thought to be 
important in regulating cytokinesis, cell motility, and cell po-
larity (40). Of the three isoforms, little is known of the func-
tional importance of the recently identifi  ed NMHC-II C.
Studies in cell culture and in isolated hearts made ischemic 
and reperfused in the absence of blood cells or sera reveal 
  evidence of cell injury to cardiomyocytes, suggesting that 
factors independent of infl  ammation can lead to cell injury 
(2, 41). One well-characterized pathway is poly(ADP ribose) 
synthetase (PARS), which is a nuclear enzyme involved in 
DNA strand break repair (3). Damage to chromatin by free 
radicals resulting from ROS, which form during hypoxia, 
leads to activation of PARS that has multiple eff  ects, in-
cluding depletion of mitochondrial ATP and eventual cell 
injury. Although the eff  ects of hypoxia on NMHC-II have 
not been reported, one possible link with generation of ROS 
and activation of the PARS pathway is that nonmuscle my-
osins, which are involved in maintaining cell morphology, 
migrate to the outer membrane after cell injury (42). Thus, 
a general explanation for the combined pathways is that 
NMHC-II is mobilized to the cell surface by hypoxia-related 
events resulting in transient exposure of the N2 region on the 
outer cell surface of endothelium and muscle cells. This ex-
posure would provide a target for circulating pathogenic IgM 
resulting in enhancement of cell injury beyond that caused by 
endogenous intracellular pathways such as PARS. We pro-
pose that the NMHC-II epitope is exposed on hypoxic cells 
and not released as a result of cell death. If the latter were the 
case, multiple other self-antigens would be released and also 
serve as targets for circulating natural IgM, which binds many 
intracellular antigens. Based on the direct visualization of vas-
cular leakage, it seems most probable that injury is initiated at 
the endothelium surface.
Expression of novel cell surface molecules in response to 
stress is not unprecedented, although examples are generally 
based on in vitro study. For example, a recent report iden-
tifi  ed mouse and human NKG2D ligands up-regulated in 
nontumor cell lines by genotoxic stress and stalled DNA rep-
lication (43). In their in vitro model, expression of the novel 
NK receptor ligands was dependent on the ataxia telangi-
ectasia, mutated pathway. Thus, they propose “a novel link 
between the immune response and processes that regulate 
genome integrity” (43). Alternatively, in our system, NMHC-
II could be released into circulation or the extracellular space 
and bound by antibody. Attempts to measure specifi  c release 
of NMHC were unsuccessful to date. As more specifi  c re-
agents are developed, it will be important to identify the 
  kinetics of exposure/release by hypoxic cells. Thus, in the ab-
sence of IgM as in RAG-1−/− mice or peptide blocking of 
IgM with N2 or P8, we speculate that cell injury is reversible 
Figure 7.  N2 peptide is protective in skeletal muscle model of RI. 
WT mice were treated in the hindlimb model of RI and administered 
  either saline, control, or N2 peptide before reperfusion. (A) Representa-
tive sections of hindlimb muscle isolated from mice pretreated with ei-
ther saline (top) or 40 μM N2 peptide (bottom). Samples were stained 
with Masson’s Trichrome for histology. Magnifi  cation, 200. (B) Injury 
score based on the percentage of injured fi  bers per 50 counted. Each 
symbol represents a single mouse. *, P < 0.05 as determined by Student’s 
t test between N2 and control peptide; P < 0.01 as determined by Stu-
dent’s t test between N2 and saline; and P < 0.05 as determined by 
ANOVA for all groups. JEM VOL. 203, January 23, 2006  149
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at least within the conditions of ischemia used in the current 
experiments. Of course, prolonged hypoxia would lead to 
  irreversible cell injury and cell death independent of the in-
nate immune system.
Although our experiments suggest that NMHC-II is the 
major antigen exposed during reversible RI, other epitopes 
are likely exposed on the surface of injured endothelium but 
in the absence of specifi  c natural IgM are insuffi   cient to me-
diate infl  ammation. Support for additional antigens comes 
from recent reports by Fleming et al.(44, 45). Using a similar 
model of mesenteric RI, they reported that murine and hu-
man antibodies specifi  c for phospholipids (PLs) and/or β-2 
glycoprotein could restore injury in Cr2−/− or RAG-1−/− 
animals. Because the murine anti-PL and β-2 antibodies are 
of the IgG subclass and were isolated from autoimmune mice 
(NZW × BxSB F1), they likely represent high-affi   nity anti-
bodies that arose as a result of autoimmune disease. Similarly, 
IgG antibodies from 5-mo-old but not 2-mo-old B6.MRL/
lpr autoimmune-prone mice are pathogenic in RI-treated 
RAG-1−/− mice. Whether natural IgM of similar specifi  city 
occur in nonautoimmune animals is unclear. However, given 
that pretreatment of WT mice with N2 or P8 peptides blocks 
injury in our two models, antibodies specifi  c for self-anti-
gens, such as PL or β-2 glycoprotein I, are not likely in-
volved in the initiating event. However, after induction of 
RI it is clear that many additional self-antigens are released 
and become targets for self-specifi  c natural IgMs. This could 
explain the observation by Fleming et al. (45) that mesenteric 
ischemic in the B6.MRL/lpr strain is more severe than WT 
controls as they express a higher level of self-reactive anti-
bodies of both IgM and IgG subclasses (46).
The pharmokinetics of N2 peptide are yet to be com-
pletely elucidated, but an initial serum concentration of  32–
40 μM is suffi   cient to block substantial injury in ischemic 
RAG-1−/− mice administered IgM CM-22 or WT mice over 
the 3 h of reperfusion. Because the peptide likely has a very 
short half-life in serum, it either binds with suffi   cient high af-
fi  nity to the IgM to inhibit recognition of ligand over the 
complete period of reperfusion, or the ligand is only exposed 
transiently on reperfusion and peptide is only required after 
initial reperfusion. The kinetics of peptide binding determined 
by Biacore assay suggest that the former is unlikely and, there-
fore, we favor the latter possibility. Earlier studies in a rat 
myocardial RI model identifi  ed increased myocardial injury 
7 d after ischemia (10). Injury was complement dependent, as 
pretreatment with a soluble inhibitor of C3 considerably re-
duced late injury. A limitation of the intestinal model is that 
injured microvilli are replaced by newly migrating entero-
cytes that emanate from stem cells in the crypts (47). Al-
though it seems likely that pretreatment with peptide will 
block late injury as it does acute, these studies will be impor-
tant to follow up in the skeletal or cardiac muscle models.
Given the highly conserved nature of the N2 region, it is 
possible that exposure of other forms of myosin Hc, such as 
smooth muscle, could also serve as a target for natural anti-
body. However, it is notable that only NMHC-II A and C 
isoforms were identifi  ed in the immune precipitation analy-
ses, suggesting that these are the major antigens exposed/ex-
pressed during ischemia, at least in the intestine. It will be 
important to characterize the IgM–self-antigen complexes in 
the hindlimb model. Natural IgM, which is a product of 
  innate lymphocytes (i.e., B-1 cells), is considered a compo-
nent of innate immunity because of its germ line–encoded 
repertoire, absence of somatic mutation, and specifi  city for 
structures highly conserved among both prokaryotes and eu-
karyotes (35–38). Therefore, it is not surprising that a highly 
conserved region of myosin could also serve as a target for 
natural IgM.
It is proposed that natural antibody recognition of the 
N2 epitope is conserved among vertebrates, as identifi  ed for 
other B-1 cells such as for T-15 specifi  city. Natural IgM of 
the T-15 specifi  city binds oxidized lipids and phosphoryl 
choline (38). Moreover, like anti–phosphoryl choline natural 
IgM, the serum levels of N2-specifi  c antibody probably also 
vary among mice. If so, it will be important to test whether 
N2-specifi  c antibody levels correlate with susceptibility to 
RI. Furthermore, we propose that this innate response to a 
stress-induced self-antigen represents a general mechanism 
referred to as “innate autoimmunity” (29, 30). This novel 
concept was recently proposed to explain a role for Toll-like 
receptors in mediating sterile infl  ammation in response to 
self-ligands (29). Our observation that a natural antibody rec-
ognizes a highly conserved self-antigen, resulting in sterile 
infl  ammation and tissue destruction, extends this notion to 
other pathways of innate recognition. Although a response to 
NMHC-II by Toll-like receptors was not examined, it is 
possible that they could participate in a secondary role as cells 
dying as a result of infl  ammation release other potential self-
ligands. Similarly, other components of innate recognition 
such as mannan-binding lectin (MBL) (48), surfactants (49, 
50), and C1q (51), which are known to bind and clear apop-
totic cells, could play a secondary role after cell injury. Re-
cently, Hart et al. reported the novel observation that injury 
in a mesenteric model of RI is dependent on MBL and com-
plement C2 but not C1q (34). Based on the importance of 
IgM and C4, it was assumed that injury was mediated via the 
classical pathway. We propose that IgM initiates the lectin 
pathway based on preliminary experiments indicating IgM 
deposition but an absence of C4 or C3 binding in MBL-a/c 
double-defi  cient mice (unpublished data). Thus, recognition 
of NMHC-II and deposition of IgM either facilitates binding 
of MBL to IgM or exposes an MBL binding site on ischemic 
tissue leading to its activation.
RI represents a major health problem because it aff  ects 
most tissues, including the intestine, myocardium, and cen-
tral nervous system, and at present there are no eff  ective ther-
apies or treatment (52). Intestinal ischemia, particularly the 
acute form, has a high mortality rate (70–90%) (53). The 
identifi  cation of a common epitope that is conserved among 
vertebrates and represents the target for natural IgM in a mu-
rine model of RI could provide a basis for development of a 
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peptide inhibits RI in two distinct tissues supports the feasi-
bility of the approach.
In summary, we have identifi  ed a conserved region of 
myosin Hc that serves as the target for natural IgM in two 
murine models of RI. It is proposed that this pathway repre-
sents a novel response by the innate immune system to self-
antigens induced by hypoxia or other forms of cell stress.
MATERIALS AND METHODS
Phage display peptide library and peptide synthesis. A 12-mer M13 
phage display library (New England BioLabs, Inc.) was screened for four 
rounds with MBL beads coated with IgM CM-22 and counterselected by one 
round of rat IgM followed by one round of IgM CM-75, according to the 
manufacturer’s recommendation. Phage clones were selected from the en-
riched pool, and the nucleotide sequence of the relevant phage gene was de-
termined for <10 clones. Selected peptides were synthesized with a purity 
>95% in the Harvard Proteomic Core or New England Peptide, Inc.
Binding assays. ELISA was performed as described previously (27). In 
brief, IgM binding to phage or phage-specifi  c peptides was determined by 
coating a 96-well plate with saturating amounts of antigen. Subsequent to 
blocking, 1 or 10 μg/ml IgM was added for 2 h at 37°C. Plates were 
washed and developed with alkaline phosphatase–labeled goat anti–mouse 
IgM (Sigma-Aldrich). To detect binding of IgM to NMHC-II, plates were 
coated with specifi  c rabbit IgG, and fresh intestinal lysate was added as a 
source of antigen. Subsequently, plates were washed, a source of natural 
IgM (i.e., IgM CM-22 or IgM CM-31) was added, and binding was detected as 
described in the previous sentence. The following rabbit antibodies were 
used: NMHC-II A and B (Covance Inc.), NMHC-II C (a gift from R. 
Adelstein, National Institutes of Health [NIH], Bethesda, MD), and pan–
myosin Hc (Sigma-Aldrich). Lysates were prepared as described in Im-
mune precipitation.
Intestinal RI model. RAG-1−/− and C57BL/6 mice used in this study 
were purchased from Jackson ImmunoResearch Laboratories and main-
tained within the mouse colony under specifi  c pathogen-free conditions at 
Harvard Medical School according to NIH guidelines on animal welfare. 
Procedures involving animals were approved by the Institutional Review 
Boards at the CBR Institute, Harvard Medical School, Massachusetts Gen-
eral Hospital, and Brigham and Women’s Hospital. Surgical protocol for RI 
was performed as previously described (27). In brief, a laparotomy is per-
formed, a microclip (125 g pressure; Roboz) is applied to the superior mes-
enteric artery, and bilateral circulation is limited with silk sutures fl  anking a 
20-cm segment of the jejuneum. After 40 min of ischemia, the microclip 
was removed, and reperfusion of the mesenteric vasculature was confi  rmed 
by the return of pulsation to the vascular arcade and a change to pink color. 
The incision was closed, and all animals were kept warm for 3 h. Reconsti-
tuted RAG-1−/− animals received either IgM mixed with peptide or saline 
in 0.2 ml volume i.v. 30 min before the initial laparotomy. WT animals were 
treated with saline or peptide i.v. 5 min before reperfusion. At the end of re-
perfusion, the ischemic segment of the jejunum was harvested, and the cen-
tral 4 cm was cut for pathological analysis.
Hindlimb RI model. 8–12-wk-old WT mice underwent 2 h of hindlimb 
ischemia and 3 h of reperfusion as previously described (28). In brief, bilat-
eral rubber bands (Latex O-Rings; Miltex Instruments) were applied above 
the greater trochanter. Rubber bands were removed, and limb reperfusion 
was confi  rmed by return of pink color. Tissues were fi  xed for 8 h in 4% 
paraformaldehyde and sectioned for Masson’s Trichrome staining. 50 indi-
vidual muscle fi  bers were counted per section, and the injury was reported 
as the number of damaged fi  bers per 50 fi  bers counted.
Histopathology and immunohistochemistry analysis. Cryostat sec-
tions of intestinal tissues were stained by hematoxylin and eosin and exam-
ined by light microscopy for mucosal damage. Pathology score was assessed 
based on a procedure modifi  ed from Chiu et al. (54) that included direct in-
spection of all microvilli over a 4-cm stretch of jejuneum, as described previ-
ously (27). In brief, the integrated injury score = S/(V + [P × 25]) × 50% + 
D/(V + [P × 25]) × 100% + (P × 25)/(V + [P × 25]) × 100%, where V = 
total number of villi; S = villi appearing with subepithelial space, defi  ned as 
an acellular space under a continuous epithelial layer and a milder form of 
damage; D = villi appearing with epithelial disruption, defi  ned as discontin-
uation of an epithelial layer of villus and a more severe form of damage; and 
P = villi lost over the length of intestine measured using a 100× fi  eld (each 
fi  eld has an average of 25 jejunal villi; thus, by aligning the intestinal wall 
through the center of each power fi  eld, an estimate of the number lost can 
be made). For immunofl  uorescence, cryosections fi  xed with 4% (wt/vol) 
paraformaldehyde were incubated for varying periods with biotin-labeled 
anti–mouse IgM (Becton Dickinson), followed by 1 h with streptavidin–
  Alexa 568 (Invitrogen). C4 deposition was detected by staining with FITC-
labeled rabbit anti-huC4c (DakoCytomation), followed by anti–rabbit–Alexa 
488 (Invitrogen). The specifi  city of anti-C4c staining was confi  rmed by 
staining serial sections with biotin-labeled anti–mouse C4 for 1 h followed 
by streptavidin–FITC (Becton Dickinson). C3 deposition was detected by 
treating with FITC-labeled anti-C3 (DakoCytomation). Sections were 
mounted in antifade mounting medium with DAPI (Invitrogen).
SPR analysis of peptide binding to antibody. IgM (IgM CM-22 or CM-31) 
antibody was immobilized by amine coupling in a chip (SPR CM5; Biacore) 
fl  owcell at a density of 33,400 response units per  33 ng/mm2 as described 
previously (55). A reference fl  ow cell was prepared by coupling of ethanol-
amine-HCl. Peptides, diluted in PBS running buff  er, were fl  owed separately 
over the IgM-coupled surface and the reference at a rate of 10 μl/min at 
25°C, with the data collection rate at 10 Hz. The injection phase had a dura-
tion of 240 s (the ends of injection phases are marked by arrow heads). Bind-
ing isotherms were derived by subtracting the response in the reference cell 
from the response of the IgM-coupled surface. After each run, the surface 
was regenerated by injecting 40 μl 0.05% (vol/vol) polyoxyethylenesorbitan 
monolaureate/PBS.
Immune precipitation. Frozen tissues were homogenized in a lysis buff  er 
containing detergent and a cocktail of enzyme inhibitors. A sample of lysate 
is analyzed for total protein content (protein assay dye; Bio-Rad Labora-
tories) to ensure similar levels of protein for analysis. Lysates are mixed with 
sepharose beads coated with rat anti–mouse IgM for 1 h at 4°C. Subse-
quently, beads were pelleted gently, washed in lysis buff  er, and boiled in 
SDS sample buff  er under reducing conditions to elute bound complexes. 
Samples were fractionated on 8% (wt/vol) polyacrylamide SDS gels and sub-
sequently fi  xed and stained with either Coomassie blue or silver stain to 
identify protein bands.
Protein identifi   cation by tandem mass spectrometry. Individual 
  Coomassie-stained bands were excised from SDS gels, destained, and sub-
jected to enzyme digestion as described previously (56). The peptides were 
separated using a nanofl  ow liquid-coupled chromatography system (CapLC; 
Waters), and amino acid sequences were determined by tandem mass spec-
trometer (Q-Tof micro; Waters). Mass spectrum (MS)/MS data were pro-
cessed and subjected to database searches using Mascot (Matrix Science) 
against the UniProtKB/Swiss-Prot, TrEMBL-NEW, or the NCBI nonre-
dundant databases.
Intestinal permeability. Intestinal permeability was determined by mea-
suring the appearance of HRP in blood (molecular mass = 40 kD; Sigma-
Aldrich) administered by gavage as described previously (57). The model 
used for investigating intestinal permeability was basically identical to the 
surgical protocol described in Intestinal RI model, except bilateral circula-
tion limitation with silk sutures was not performed to maintain an open lu-
men during the study. In brief, 10 min before intestinal RI was induced, 
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(pH 7.4) containing 2 mg/ml HRP by gavage. To test the blocking eff  ect of 
N2 peptide in intestinal RI, WT C57BL/6 mice were treated with saline or 
peptide (fi  nal serum concentration = 40 µM) in a volume of 100 µl i.v. 5 
min before reperfusion. Blood samples were obtained in a capillary tube 3 h 
after reperfusion by retroorbital puncture. Blood samples were allowed to 
clot overnight at 4°C and centrifuged (3,000 rpm) for 10 min. Serum sam-
ples were diluted and added to a 96-well microplate (Nalge Nunc) precoated 
with goat anti-HRP antibody (1:2,500 dilution; Sigma-Aldrich). The plate 
was then incubated for 2 h at 37°C, after which the wells were washed three 
times with phosphate-buff  ered saline (pH 7.4) and 0.1% Tween 20. HRP 
activity was determined by adding 100 µl of reagent (TMB One-Step Sub-
strate System; DakoCytomation) for 15 min, and the reaction was stopped 
with 100 µl 2N H2SO4. The concentration of HRP was determined by 
spectrometry at 450 nm.
Vascular leakage. Leakage was determined in real time using an intravital 
imaging approach combined with a novel scanning laser confocal microscope 
(prototype scanner from Olympus Corp.) and a vascular probe (AngioSense 
680; VisEn Medical) as described previously (58). Mice were anesthetized 
with a 0.3-ml i.p. injection of 15 mg/ml ketamine Hcl and 3 mg/ml xylazine 
and injected i.v. with AngioSense 680 (10 nmol/mouse) and Rhodamine 6G 
(Invitrogen) 5 min before reperfusion. Mice treated for intestinal RI (see In-
testinal permeability) and sham controls were prepared for imaging before re-
perfusion by making a small incision within the wall of the exposed jejuneum 
and inserting the “stick-lens” (1.3 mm diameter) of the prototype confocal 
setup. Imaging of the microvilli was initiated 15 min after reperfusion and 
continued for up to 45 min. Images were prepared at varying time points after 
reperfusion. Results from representative images of the three groups of mice 
(i.e., sham, saline, and N2 peptide) were analyzed by imaging software (Image 
J version 1.34; Wayne Rasband, NIH, Bethesda, MD) by taking 10 measure-
ments of representative fi  elds of view, and the intensity of red dye within the 
target vessels (V) versus surrounding background (B) tissue was determined. 
Results were calculated as ratio of V/B intensity ± SD.
Statistical analysis. Data in all fi  gures (except Fig. 6, in which SD is used) 
are expressed as means ± SEM. Statistical comparisons between groups were 
made by Student’s t test, and ANOVA was used for comparisons of multiple 
groups. P < 0.05 was considered signifi  cant.
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